Mimacom is delighted to attend the Pharmaceutical Automation and Digitalisation Congress 2026. The event brings together pharmaceutical decision-makers from major pharma companies, contract manufacturers, API suppliers, and digital transformation leaders. Attendance is curated, and discussions take place through B2B meetings, case study sessions, and strategic panels.
The pharma sector is navigating a sustained shift toward digital-first operations, where compliance, data governance, and clinical software are central to competitive positioning. This congress is one of the few forums where those pressures are examined with the operational depth they require.
Mimacom's work in pharma spans regulated software medical devices, data platform architecture, and AI implementation in life sciences. The congress agenda reflects priorities we encounter directly in client delivery, which is why these conversations are relevant to our team.
Digital transformation in pharma is no longer optional. Regulatory pressure, supply chain fragility, and the demand for real-world evidence are accelerating the need for robust, compliant digital infrastructure. AUTOMA+ 2026 brings together the organizations shaping that infrastructure, with an agenda focused on where delivery is actually happening.
The agenda of the Pharmaceutical Automation and Digitalisation Congress 2026 reflects the implementation reality facing pharma organizations today.
Smart supply chain and logistics
Supply chain reliability in pharma depends on data integrity at every stage, from raw material sourcing to patient delivery. The congress addresses how organizations are integrating smart labeling, real-time tracking, and anti-counterfeiting technologies into compliant supply chain operations. For global pharma, these are not experimental programs but active infrastructure decisions. Read more on supply chain data integration.
Pharma digital compliance
Regulatory compliance is increasingly a software problem. Systems that manage dosing data, patient outcomes, and manufacturing records must be designed for auditability from the outset. The congress examines how compliance frameworks are being embedded into digital architecture rather than added as a review step after deployment.
Digital health and therapeutics
Software as a medical device (SaMD) is a growing category, with organizations developing clinical tools that require FDA clearance or CE marking. The sessions at AUTOMA+ 2026 explore how digital therapeutics are being validated, deployed, and maintained across regulated markets.
Mimacom is participating in AUTOMA+ 2026 based on its experience building regulated software medical devices and data platforms for pharmaceutical and life sciences organizations.
The topics being discussed are grounded in delivery experience across the pharma value chain. The focus is on implementation and measurable outcomes.
Regulated software medical devices for Takeda
Working with Takeda Pharmaceuticals since 2015, Mimacom developed two regulated software medical devices for chronic condition management: myPKFiT, the first FDA-cleared pharmacokinetic dosing software for hemophilia A, and the VDZ-CDST calculator for Crohn's disease care.
Both are built on a shared cloud-native microservice architecture, deployed across 50+ countries from a single compliant codebase. myPKFiT reduced the number of blood draws required for treatment planning from 11 to 2 per cycle. Each device was developed within a rigorous quality management system, with teams spanning regulatory, clinical, and engineering disciplines.
Manufacturing data integration
For pharmaceutical manufacturers running fragmented data across R&D, production, and supply chain, Mimacom designs integration architectures that work within regulatory constraints without disrupting live operations.
This means event-driven architectures connecting manufacturing execution systems with enterprise platforms, zero-trust designs for production environments, and observability strategies that give engineering and operations teams consistent visibility across the manufacturing lifecycle. Clients in this space include Straumann, Merck, and Kernpharma.
R&D AI acceleration
For pharmaceutical organizations where AI initiatives stall on fragmented or ungoverned research data, Mimacom builds the ML platform infrastructure that makes AI viable in regulated environments.
This begins with a governed, unified data layer across research and lab systems. Without that foundation, AI models cannot be validated or operated within pharmaceutical quality management constraints.
These projects share a common thread: each required AI, data, or software to operate correctly within pharmaceutical regulatory constraints. That is the conversation AUTOMA+ 2026 is structured around.
Our team will be discussing these projects and related approaches during the event. If you are attending, we welcome the opportunity to connect.
Pharma organizations face a consistent challenge: digital ambitions are broad, but compliance constraints are specific and non-negotiable. Mimacom's approach is to treat regulatory requirements as architectural constraints from day one, not as a review step applied after deployment. That perspective runs through the architecture decisions and the regulatory documentation we produce in every pharma project.
We look forward to meeting the delegates in Zürich on November 16–17.